El trading conlleva riesgos
Las inversiones conllevan riesgos y no son adecuadas para todos los inversores. Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
El trading conlleva riesgos
Las inversiones conllevan riesgos y no son adecuadas para todos los inversores. Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
Español (Latinoamérica)
Lonza Group AG
Cerrado
SectorSalud
562.6 -1.02
Resumen
Variación precio
24h
Mínimo
562.2
Máximo
565.8
Ingresos | 307M |
|---|---|
Ventas | 3.5B |
P/B Media del Sector | 62.626 39.564 |
BPA | 4.31 |
Rentabilidad por dividendo | 0.71 |
Margen de beneficio | 8.729 |
Empleados | 17,995 |
EBITDA | 764M |
Recomendaciones | Compra Fuerte |
|---|---|
Estimación a 12 meses | +14.68% upside |
Rentabilidad por dividendo Media del Sector | 0.71% 2.40% |
|---|---|
Próximas Ganancias | 23 jul 2025 |
Capitalización de Mercado | -2.9B 39B |
|---|---|
Apertura anterior | 563.62 |
Cierre anterior | 562.6 |
Noticias sobre sentimiento de mercado
By Acuity
15%
85%
25 / 376 Clasificación en Healthcare
Lonza Group AG Gráfico
El rendimiento pasado no es un indicador fiable de resultados futuros.
Noticias Relacionadas
Lonza Group AG Esperado
Precio Objetivo
By TipRanks
14.68% repunte
Estimación a 12 meses
Media 653 CHF 14.68%
Máximo 705 CHF
Mínimo 609 CHF
De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Lonza Group AG Dist en los últimos 3 meses.
Sentimiento
By Acuity
25 / 376 Clasificación en Salud
Noticias sobre sentimiento de mercado
Coyuntura alcista notoria
Volatilidad
Por debajo de la media
Volumen de Noticias (RCV)
Por encima de la media
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de Lonza Group AG
Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. This segment also supports customers across various aspects of design, development, and manufacturing, including particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.